Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Acquired by Cerity Partners LLC

Cerity Partners LLC boosted its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 28.7% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 40,307 shares of the medical equipment provider's stock after purchasing an additional 8,999 shares during the quarter. Cerity Partners LLC's holdings in Zimmer Biomet were worth $4,351,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Ashton Thomas Securities LLC purchased a new position in shares of Zimmer Biomet in the 3rd quarter worth $28,000. Bangor Savings Bank bought a new stake in Zimmer Biomet during the third quarter worth approximately $31,000. Family Firm Inc. purchased a new stake in Zimmer Biomet during the second quarter valued at approximately $33,000. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA purchased a new position in shares of Zimmer Biomet in the 2nd quarter worth approximately $43,000. Finally, Ridgewood Investments LLC purchased a new stake in Zimmer Biomet during the 2nd quarter valued at $43,000. Hedge funds and other institutional investors own 88.89% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on ZBH. Evercore ISI decreased their price target on shares of Zimmer Biomet from $113.00 to $110.00 and set an "in-line" rating for the company in a research report on Tuesday, October 1st. Wolfe Research started coverage on Zimmer Biomet in a research report on Tuesday, September 10th. They issued a "peer perform" rating for the company. Royal Bank of Canada increased their price target on Zimmer Biomet from $120.00 to $125.00 and gave the company an "outperform" rating in a research note on Monday, November 4th. Truist Financial upped their price objective on shares of Zimmer Biomet from $112.00 to $117.00 and gave the company a "hold" rating in a report on Friday, November 1st. Finally, Oppenheimer dropped their target price on shares of Zimmer Biomet from $145.00 to $135.00 and set an "outperform" rating on the stock in a research report on Tuesday, October 15th. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $123.22.

Zimmer Biomet Trading Up 0.1 %

Shares of ZBH stock traded up $0.08 on Friday, hitting $112.10. The stock had a trading volume of 504,046 shares, compared to its average volume of 1,494,978. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.36 and a quick ratio of 0.70. The firm has a market capitalization of $22.32 billion, a P/E ratio of 21.31, a P/E/G ratio of 2.06 and a beta of 1.02. The company's 50 day moving average price is $107.29 and its 200-day moving average price is $109.45. Zimmer Biomet Holdings, Inc. has a 1 year low of $101.47 and a 1 year high of $133.90.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $1.74. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The company had revenue of $1.82 billion during the quarter, compared to the consensus estimate of $1.80 billion. During the same quarter in the previous year, the firm earned $1.65 earnings per share. The firm's quarterly revenue was up 4.1% on a year-over-year basis. Analysts anticipate that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current year.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.